In this brief review, we compile and discuss the evidence supporting a pivotal role of disrupted Nrf2 signaling in orchestrating glia-mediated ROS increase and mitochondrial dysfunction at the onset of MS. This evidence concerns the gene NFE2L2 and myeloid sarcoma.